Form 4: Janux Therapeutics Director Natasha Hernday Receives Equity Compensation Awards

Janux Therapeutics, Inc. Director Natasha Hernday reported the acquisition of 3,750 restricted stock units and 11,667 stock options on June 11, 2025, as part of her compensation.

Summary

• Natasha Hernday, a Director of Janux Therapeutics, Inc. (JANX), reported the acquisition of equity awards on June 11, 2025.
• She was granted 3,750 restricted stock units (RSUs) at a price of $0, which represent a contingent right to receive one share of common stock per RSU.
• These RSUs will vest on the earlier of June 11, 2026, or the date of the next annual meeting of the Issuer's stockholders, subject to continuous service.
• Additionally, she was granted 11,667 stock options with an exercise price of $25.46.
• These stock options will vest in equal monthly installments over 12 months following June 11, 2025, or fully vest on the date of the next annual meeting, subject to continuous service.
• Following these transactions, Ms. Hernday beneficially owns 8,731 shares of common stock and 11,667 stock options.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: The grant of equity awards to a director is a positive step in aligning management and board interests with shareholder value, reflecting standard compensation practices and incentivizing long-term commitment. It is a routine, expected event.

Positives

• The grant of equity awards to Director Natasha Hernday aligns her interests with the long-term performance and shareholder value of Janux Therapeutics.
• The RSUs were granted at a price of $0, providing direct equity ownership upon vesting without an initial cash outlay for the recipient.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged and transparent trading plan.

Negatives

• The equity awards are subject to vesting conditions, requiring continuous service to realize the full benefit.
• The stock options have an exercise price of $25.46, meaning they will only have intrinsic value if the stock price exceeds this amount.

Risks

• Vesting of both RSUs and stock options is contingent upon the Reporting Person's continuous service with the Issuer.
• The value of the stock options is subject to the future market price of Janux Therapeutics' common stock, posing a risk if the stock price does not exceed the exercise price of $25.46.

Future Outlook

The vesting schedules for the granted restricted stock units and stock options indicate a future alignment of the director's compensation with the long-term performance and strategic objectives of Janux Therapeutics.

Industry Context

The grant of equity awards to directors is a standard practice in publicly traded companies, particularly within the biotechnology sector, serving as a key component of compensation to attract, retain, and incentivize board members by aligning their interests with shareholder value.

Comparison to Industry Standards

• The grant of restricted stock units and stock options is a common and widely accepted form of equity compensation for directors in the biotechnology and pharmaceutical industries.
• This compensation structure is designed to align the interests of the board members with those of the shareholders by incentivizing long-term company performance and stock appreciation.
• The vesting schedules (over 12 months for options, or earlier of one year/next annual meeting for RSUs) are typical for director equity awards, promoting retention and sustained engagement.
• While specific comparable companies or projects are not mentioned in the filing, this type of equity grant is standard practice across publicly traded companies, particularly in growth-oriented sectors like biotech, to attract and retain qualified board members.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with the long-term performance of the company, potentially leading to more shareholder-friendly decisions and increased value.
• Employees: While not directly impacting general employees, the compensation structure for leadership can influence overall company culture and compensation philosophy.
• Management: The director's continued engagement and incentivization through equity awards can support strategic initiatives and corporate governance.

Next Steps

• Vesting of 3,750 restricted stock units on the earlier of June 11, 2026, or the date of the next annual meeting of stockholders, subject to continuous service.
• Vesting of 11,667 stock options in equal monthly installments over 12 months following June 11, 2025, or fully vested on the date of the next annual meeting of stockholders, subject to continuous service.

Key Dates

Keywords

Janux Therapeutics, JANX, SEC Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Director Compensation, Natasha Hernday, 10b5-1 Plan